RESUMO
We present a case of a full-term newborn with complex congenital heart defects, including single-ventricle physiology and discontinuous pulmonary arteries. Prompt surgical intervention was performed, which involved pulmonary neoconfluence with autologous pericardium graft and systemic-to-pulmonary shunt placement. However, postoperative complications required stenting to address pulmonary artery stenosis.
RESUMO
Pulmonary atresia with an intact ventricular septum is characterised by heterogeneity in right ventricle morphology and coronary anatomy. In some cases, the presence of ventriculocoronary connections may promote coronary artery stenosis or interruption, and aortic diastolic pressure may not be sufficient to drive coronary blood flow. This requires a correct evaluation (currently done by angiography) which depends on whether the patient can be offered decompression of the right ventricle. To date, there is no objective method to do so, so we designed a percutaneous, transitory technique with the purpose of occluding the transtricuspid anterograde flow. The manoeuverer was performed in a 25-day-old female with pulmonary atresia with intact ventricular septum, right ventricle at suprasystemic level, and selective coronarography was not conclusive, the anterior descendant with stenosis in its middle third and from this point, thinner with to-fro flow. Occlusion was performed with a balloon catheter. We re-evaluated the coronary flow and the normalised anterior descendant flow. We hope that with this new method, we can give a more accurate diagnosis and determine the cases in which the coronary circulation is truly not right ventricle dependent to offer a greater number of patients biventricular or 1.5 ventricular repairs and thereby improve their quality of life and survival, the ones that turn out to be right ventricular dependant; offer them an early reference for cardiac transplant or in case it is not available to consider univentricular palliation knowing that this probably would not reduce the risk of ischaemia and/or death over time.
Assuntos
Cardiopatias Congênitas , Atresia Pulmonar , Septo Interventricular , Humanos , Feminino , Atresia Pulmonar/diagnóstico por imagem , Atresia Pulmonar/cirurgia , Septo Interventricular/diagnóstico por imagem , Septo Interventricular/cirurgia , Ventrículos do Coração , Qualidade de Vida , Resultado do Tratamento , Circulação CoronáriaRESUMO
Patent ductus arteriosus is the most common cardiac anomaly in our country. In the last few decades, there has been a lot of interest in developing less invasive techniques like video-assisted thoracoscopic clipping; nevertheless, this also has some complications. We present an 8-year-old female, which had been treated with video-assisted thoracoscopic clipping of patent ductus arteriosus. Five years later, she presented with a large aneurysm of the ductus arteriosus extending to the pulmonary trunk and a residual patent ductus arteriosus. A Cardia ASD occluder of 24 mm was placed in the aneurysm, and the residual ductus arteriosus was then closed with an Amplatzer Plug vascular II device of 10 mm, with a good outcome. The development of an aneurysm after video-assisted patent ductus arteriosus closure is apparently a non-reported complication; therefore, there are also no reports for its treatment. That is why we present this case as an option for its resolution.
Assuntos
Aneurisma , Permeabilidade do Canal Arterial , Canal Arterial , Dispositivo para Oclusão Septal , Feminino , Humanos , Criança , Permeabilidade do Canal Arterial/cirurgia , Artéria Pulmonar , Cateterismo Cardíaco/métodos , Resultado do TratamentoRESUMO
Introducción: La papilomatosis respiratoria recurrente es el crecimiento de lesiones papilomatosas en el tracto aerodigestivo causada por el virus del papiloma humano, aparece más entre los 3 y 6 años (juvenil) y entre la tercera y quinta décadas (adulta). Los síntomas suelen ser disfonía y dificultad respiratoria. La terapéutica consiste en la resección de lesiones y terapia adyuvante (bevacizumab e interferón). Su curso es variable, tiende a recidivar y maligniza en 3-7%, más en adultos. Objetivos: Describir resultados terapéuticos de la papilomatosis respiratoria recurrente en nuestro servicio. Materiales y métodos: Estudio observacional, descriptivo con asociación cruzada, transversal, retrospectivo, muestreo no probabilístico de casos consecutivos, de pacientes con papilomatosis respiratoria recurrente operados en la Cátedra y Servicio Otorrinolaringología del Hospital de Clínicas en el periodo 2005-2020. Resultados: Se estudiaron 40 pacientes, 65% hombres y 35% mujeres; 35% adultos y 65% juveniles. La media de edad fue 16,05±18,042 años; en los casos juveniles fue 4,69±2,908 años, en los adultos 37,14±14,94 años. Se observaron alteraciones de la voz en el 100% y de la mecánica respiratoria en el 72,5%. Se contabilizaron 119 procedimientos, en 11 pacientes se realizó solamente resección, 29 con adyuvancia, de estos 22,5% recibieron bevacizumab y 50% interferón. No hubo diferencia significativa en la media de tiempo sin lesiones entre jóvenes y adultos (p>0,05), pero si según la terapéutica con tendencia favorable con la adyuvancia, sobre todo con bevacizumab. Se constató displasia en 10% y malignización en 2,5%. La afectación fue: glotis 100% (cuerda vocal derecha 92,5%, izquierda 82,5%, ambas 77,5%, comisura anterior 62,5%), supraglotis 20% y subglotis 10%. El promedio de número de áreas afectas fue 3,34±1,274, hubo una diferencia significativa (p<0,05) entre los casos adultos (2,071±0,379) y juveniles (3,846±1,015) constatándose mayor afectación en este último. Conclusión: La mayor parte fueron casos juveniles masculinos. Las zonas más afectas fueron la glotis, sobre todo cuerdas vocales. En jóvenes se vio mayor número de regiones afectas. Todos presentaban disfonía o afonía, seguido por dificultad respiratoria. Las terapéuticas fueron resección quirúrgica sola o asociada a adyuvancia (bevacizumab o Interferón). El tiempo de recurrencia fue mayor al emplear adyuvancia terapéutica con tendencia favorable hacia el bevacizumab. La malignización ocurrió en un caso.
Introduction: Recurrent respiratory papillomatosis is the growth of papillomatous lesions in the aerodigestive tract caused by human papillomavirus, appears more between the ages of 3 and 6 years (juvenile) and between the third and fifth decades (adult). Symptoms are usually dysphonia and respiratory distress. The therapy consists of resection of lesions and adjuvant therapy (bevacizumab and interferon). Its course is variable, it tends to recur and malignancy occurs in 3-7%, more in adults. Objectives: To describe therapeutic results of recurrent respiratory papillomatosis in our service. Materials and methods: Observational, descriptive, cross-sectional, cross-sectional, retrospective, retrospective, non-probabilistic sampling of consecutive cases, of patients with recurrent respiratory papillomatosis operated in the Otorhinolaryngology Department of the Hospital de Clínicas in the period 2005-2020. Results: We studied 40 patients, 65% male and 35% female; 35% adults and 65% juveniles. Mean age was 16.05±18.042 years. In juvenile cases the mean age was 4.69±2.908 years, in adults 37.14±14.94 years. Voice alterations were observed in 100% and respiratory mechanics in 72.5%. There were 119 procedures, 11 laryngeal microsurgery alone, 29 associated with adjuvant, of these 22.5% received bevacizumab and 50% interferon. There was no significant difference in the mean time without lesions between young people and adults (p>0.05), but there was a favorable trend with adjuvant therapy, especially with bevacizumab. Dysplasia was found in 10% and malignization in 2.5%. The involvement was: glottis 100% (right vocal cord 92.5%, left 82.5%, both 77.5%, anterior commissure 62.5%), supraglottis 20% and subglottis 10%. The average number of affected areas was 3.34±1.274, there was a significant difference (p<0.05) between adult (2.071±0.379) and juvenile (3.846±1.015) cases, with greater involvement in the latter. Conclusion: Most of the cases were juvenile male cases. The most affected areas were the glottis, especially vocal cords. A greater number of affected regions were seen in young people. All presented dysphonia or aphonia, followed by respiratory distress. Therapeutics were surgical resection alone or associated with adjuvant therapy (bevacizumab or interferon). The time to recurrence was longer when adjuvant therapy was used, with a favorable trend towards bevacizumab. Malignization occurred in one case.
Assuntos
Papiloma , Otolaringologia , Papiloma/imunologia , Mecânica Respiratória , BevacizumabRESUMO
Introduction Hashimoto thyroiditis (HT) shares many characteristics with papillary thyroid carcinoma (PTC), and some studies show that, when associated, PTC is diagnosed mostly with smaller lesions and multifocal pattern. Objective To evaluate the relationship between HT and PTC. Methods A retrospective study of 155 patients who underwent total thyroidectomy from 2009 to 2015. Demographical, clinical and ultrasonographical data, as well as anatomopathological findings were evaluated. Results There were signs of thyroidits in 35 patients, and 114 patients had a unifocal disease. There was no statistical significance between the variables studied and thyroiditis. However, when compared with the occurrence of unifocal or multifocal lesions, there was statistical significance regarding age ( p = 0.038) and mass ( p = 0.031). There was no direct relationship between thyroiditis and multifocality ( p = 0.325) nor between thyroiditis and cervical extension of the disease ( p = 0.300 e p = 0.434). Conclusion There was no relationship between thyroiditis and multifocality in cases of PTC.
RESUMO
Abstract Introduction Hashimoto thyroiditis (HT) shares many characteristics with papillary thyroid carcinoma (PTC), and some studies show that, when associated, PTC is diagnosed mostly with smaller lesions and multifocal pattern. Objective To evaluate the relationship between HT and PTC. Methods A retrospective study of 155 patients who underwent total thyroidectomy from 2009 to 2015. Demographical, clinical and ultrasonographical data, as well as anatomopathological findings were evaluated. Results There were signs of thyroidits in 35 patients, and 114 patients had a unifocal disease. There was no statistical significance between the variables studied and thyroiditis. However, when compared with the occurrence of unifocal or multifocal lesions, there was statistical significance regarding age (p = 0.038) and mass (p = 0.031). There was no direct relationship between thyroiditis and multifocality (p = 0.325) nor between thyroiditis and cervical extension of the disease (p = 0.300 e p = 0.434). Conclusion There was no relationship between thyroiditis and multifocality in cases of PTC.
Assuntos
Aneurisma Coronário , Paralisia Facial , Síndrome de Linfonodos Mucocutâneos , Constrição Patológica/complicações , Aneurisma Coronário/complicações , Aneurisma Coronário/diagnóstico , Angiografia Coronária , Vasos Coronários , Nervo Facial , Paralisia Facial/complicações , Paralisia Facial/etiologia , Humanos , Lactente , Síndrome de Linfonodos Mucocutâneos/complicações , Síndrome de Linfonodos Mucocutâneos/diagnósticoRESUMO
AZD8871 is a novel muscarinic antagonist and ß 2-adrenoceptor agonist in development for chronic obstructive pulmonary disease. This study describes the pharmacological profile of AZD8871 in in vitro and in vivo assays. AZD8871 is potent at the human M3 receptor (pIC50 in binding assays: 9.5) and shows kinetic selectivity for the M3 (half-life: 4.97 hours) over the M2 receptor (half-life: 0.46 hour). It is selective for the ß 2-adrenoceptor over the ß 1 and ß 3 subtypes (3- and 6-fold, respectively) and shows dual antimuscarinic and ß 2-adrenoceptor functional activity in isolated guinea pig tissue (pIC50 in electrically stimulated trachea: 8.6; pEC50 in spontaneous tone isolated trachea: 8.8, respectively), which are sustained over time. AZD8871 exhibits a higher muscarinic component than batefenterol in human bronchi, with a shift in potency under propranolol blockade of 2- and 6-fold, respectively, together with a persisting relaxation (5.3% recovery at 8 hours). Nebulized AZD8871 prevents acetylcholine-induced bronchoconstriction in both guinea pig and dog with minimal effects on salivation and heart rate at doses with bronchoprotective activity. Moreover, AZD8871 shows long-lasting effects in dog, with a bronchoprotective half-life longer than 24 hours. In conclusion, these studies demonstrate that AZD8871 is a dual-acting molecule with a high muscarinic component and a long residence time at the M3 receptor; moreover, its preclinical profile in animal models suggests a once-daily dosing in humans and a favorable safety profile. Thus, AZD8871 has the potential to be a next generation of inhaled bronchodilators in respiratory diseases.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/efeitos adversos , Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Antagonistas Muscarínicos/efeitos adversos , Antagonistas Muscarínicos/farmacologia , Quinolinas/efeitos adversos , Quinolinas/farmacologia , Receptor Muscarínico M3/antagonistas & inibidores , Receptores Adrenérgicos beta 2/metabolismo , Segurança , Triazóis/efeitos adversos , Triazóis/farmacologia , Administração por Inalação , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Agonistas de Receptores Adrenérgicos beta 2/farmacocinética , Animais , Brônquios/efeitos dos fármacos , Brônquios/fisiologia , Sistema Cardiovascular/efeitos dos fármacos , Cães , Cobaias , Humanos , Masculino , Antagonistas Muscarínicos/administração & dosagem , Antagonistas Muscarínicos/farmacocinética , Quinolinas/administração & dosagem , Quinolinas/farmacocinética , Receptor Muscarínico M2/metabolismo , Distribuição Tecidual , Traqueia/efeitos dos fármacos , Traqueia/fisiologia , Triazóis/administração & dosagem , Triazóis/farmacocinéticaRESUMO
To provide new insight into the pathophysiological mechanisms underlying gas emboli (GE) in bycaught loggerhead sea turtles (Caretta caretta), we investigated the vasoactive characteristics of the pulmonary and systemic arteries, and the lung parenchyma (LP). Tissues were opportunistically excised from recently dead animals for in vitro studies of vasoactive responses to four different neurotransmitters: acetylcholine (ACh; parasympathetic), serotonin (5HT), adrenaline (Adr; sympathetic) and histamine. The significant amount of smooth muscle in the LP contracted in response to ACh, Adr and histamine. The intrapulmonary and systemic arteries contracted under both parasympathetic and sympathetic stimulation and when exposed to 5HT. However, proximal extrapulmonary arterial (PEPA) sections contracted in response to ACh and 5HT, whereas Adr caused relaxation. In sea turtles, the relaxation in the pulmonary artery was particularly pronounced at the level of the pulmonary artery sphincter (PASp), where the vessel wall was highly muscular. For comparison, we also studied tissue response in freshwater sliders turtles (Trachemys scripta elegans). Both PEPA and LP from freshwater sliders contracted in response to 5HT, ACh and also Adr. We propose that in sea turtles, the dive response (parasympathetic tone) constricts the PEPA, LP and PASp, causing a pulmonary shunt and limiting gas uptake at depth, which reduces the risk of GE during long and deep dives. Elevated sympathetic tone caused by forced submersion during entanglement with fishing gear increases the pulmonary blood flow causing an increase in N2 uptake, potentially leading to the formation of blood and tissue GE at the surface. These findings provide potential physiological and anatomical explanations on how these animals have evolved a cardiac shunt pattern that regulates gas exchange during deep and prolonged diving.
Assuntos
Mergulho/fisiologia , Artéria Pulmonar/efeitos dos fármacos , Tartarugas/fisiologia , Acetilcolina/farmacologia , Animais , Embolia Aérea/etiologia , Epinefrina/farmacologia , Histamina/farmacologia , Pulmão/irrigação sanguínea , Nitrogênio/metabolismo , Serotonina/farmacologiaRESUMO
OBJECTIVES: Androgen deprivation therapy (ADT) in prostate cancer is associated with the appearance of different adverse effects. Among these effects, notable ones that may affect metabolism are osteoporosis and metabolic syndrome. The aim of this study is to analyse lithogenic risk markers three months after initiating treatment with LHRH analogue. METHODS: Pilot study encompassing 15 prostate cancer patients who were candidates for ADT, which they received in the form of quarterly doses of goserelin 10.8 mg. A blood and urine analyses for lithogenic risk, bone and metabolic markers were carried out, as was a study of metabolic syndrome criteria. Statistical analysis was performed with SPSS 17.0, taking P≤.05 to be statistically significant. RESULTS: Patients included in the study had a mean age of 72.46 ± 6.61 years. We observed a significant increase in the percentage of metabolic syndrome (20% versus 46.7%; P<.05) and insulin resistance index (1.87 versus 2.96; P=.01) at 3 months treatment. There was a notable increase in bone remodelling markers and significant increases in 24 h urinary calcium values (9.46 versus 14.57 mg/dl; P=.008), 24 h urinary calcium excretion index (0.10 versus 0.13 mg/dl GF [glomerular filtration]; P=.01) and the fasting calcium/ creatinine ratio (0.107 versus 0.195; P=.007), without any changes to other lithogenous risk markers. CONCLUSIONS: Androgen deprivation therapy can lead to the short-term appearance, primarily when fasting, of hypercalciuria in prostate cancer patients, possibly in association with bone metabolism.
Assuntos
Cálcio/urina , Neoplasias da Próstata/urina , Idoso , Antagonistas de Androgênios/uso terapêutico , Hormônio Liberador de Gonadotropina/análogos & derivados , Humanos , Masculino , Projetos Piloto , Estudos Prospectivos , Neoplasias da Próstata/complicações , Neoplasias da Próstata/tratamento farmacológico , Fatores de Risco , Fatores de Tempo , Urolitíase/etiologiaRESUMO
OBJETIVOS: La terapia de deprivación androgénica en el cáncer de próstata se relaciona con la aparición de diferentes efectos adversos. En el ámbito metabólico destacan la aparición de osteoporosis y síndrome metabólico. El objetivo de este estudio es analizar los marcadores de riesgo litógeno a los 3 meses de haber iniciado tratamiento con análogo LHRH. MÉTODOS: Estudio piloto que incluye a 15 pacientes con cáncer de próstata subsidiarios de tratamiento con deprivación androgénica que se realiza con goserelina 10,8 mg trimestral. Se realiza estudio en sangre y orina de marcadores de riesgo litógeno, marcadores óseos y metabólicos, así como estudio de criterios de síndrome metabólico. Análisis estadístico con programa SPSS 17.0, considerando p≤0,05 como significación estadística. RESULTADOS: La edad media de los pacientes incluidos fue de 72,46 ± 6,61 años. Se observó un aumento significativo del porcentaje de síndrome metabólico a los 3 meses de tratamiento (20% versus 46,7%; p < 0,05), así como del índice de resistencia a la insulina (1,87 versus 2,96; p = 0,01). Destaca un aumento de los marcadores de remodelado óseo, así como un aumento significativo de la calciuria (9,46 versus 14,57 mg/dl; p = 0,008), del índice de excreción urinario de calcio (0,10 versus 0,13 mg/dl FG; p = 0,01) y del cociente calcio/creatinina de ayunas (0,107 versus 0,195; p = 0,007), sin modificaciones en otros marcadores de riesgo litógeno. CONCLUSIÓN: La terapia de deprivación androgénica puede inducir a corto plazo incremento de la calciuria, fundamentalmente de ayunas, en este tipo de pacientes en posible relación con alteración del metabolismo óseo
OBJECTIVES: Androgen deprivation therapy (ADT) in prostate cancer is associated with the appearance of different adverse effects. Among these effects, notable ones that may affect metabolism are osteoporosis and metabolic syndrome. The aim of this study is to analyse lithogenic risk markers three months after initiating treatment with LHRH analogue. METHODS: Pilot study encompassing 15 prostate cancer patients who were candidates for ADT, which they received in the form of quarterly doses of goserelin 10.8 mg. A blood and urine analyses for lithogenic risk, bone and metabolic markers were carried out, as was a study of metabolic syndrome criteria. Statistical analysis was performed with SPSS 17.0, taking P≤.05 to be statistically significant. RESULTS: Patients included in the study had a mean age of 72.46 ± 6.61 years. We observed a significant increase in the percentage of metabolic syndrome (20% versus 46.7%; P<.05) and insulin resistance index (1.87 versus 2.96; P=.01) at 3 months treatment. There was a notable increase in bone remodelling markers and significant increases in 24 h urinary calcium values (9.46 versus 14.57 mg/dl; P=.008), 24 h urinary calcium excretion index (0.10 versus 0.13 mg/dl GF [glomerular filtration]; P=.01) and the fasting calcium/ creatinine ratio (0.107 versus 0.195; P=.007), without any changes to other lithogenous risk markers. CONCLUSIONS: Androgen deprivation therapy can lead to the short-term appearance, primarily when fasting, of hypercalciuria in prostate cancer patients, possibly in association with bone metabolism
Assuntos
Humanos , Masculino , Idoso , Cálcio/urina , Neoplasias da Próstata/urina , Antagonistas de Androgênios/uso terapêutico , Hormônio Liberador de Gonadotropina/análogos & derivados , Projetos Piloto , Estudos Prospectivos , Neoplasias da Próstata/complicações , Neoplasias da Próstata/tratamento farmacológico , Fatores de Risco , Fatores de Tempo , Urolitíase/etiologiaRESUMO
LAS190792 is a novel muscarinic antagonist and ß2-adrenoceptor agonist in development for chronic respiratory diseases. This study investigated the pharmacological profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol. LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays). It is selective for the ß2-adrenoceptor over the ß1-and ß3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compounds (pEC50 in spontaneous tone isolated trachea: 9.6). The relaxant potency of LAS190792 in electrically stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol slightly higher than batefenterol (pIC50 of 8.3 versus 7.9 in human tissue). LAS190792 exhibits a sustained duration of action in isolated tissue longer than that of batefenterol. Nebulized LAS190792 inhibits acetylcholine-induced bronchoconstriction in dog with minimal cardiac effects and sustained bronchodilation (t1/2: 13.3 h). In conclusion, these studies suggest that LAS190792 is a dual-acting muscarinic antagonist ß2-adrenoceptor agonist that has the potential to be a next generation bronchodilator with long-lasting effects and wide safety margin in humans.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Cicloexanos/farmacologia , Antagonistas Muscarínicos/farmacologia , Quinolinas/farmacologia , Tiofenos/farmacologia , Acetilcolina/farmacologia , Administração por Inalação , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Animais , Broncoconstrição/efeitos dos fármacos , Cicloexanos/administração & dosagem , Cães , Cobaias , Meia-Vida , Humanos , Concentração Inibidora 50 , Masculino , Antagonistas Muscarínicos/administração & dosagem , Quinolinas/administração & dosagem , Receptor Muscarínico M3/antagonistas & inibidores , Doenças Respiratórias/tratamento farmacológico , Doenças Respiratórias/fisiopatologia , Tiofenos/administração & dosagemRESUMO
Antecedentes y objetivo: El tratamiento de privación androgénica en el cáncer de próstata se asocia a la aparición de diferentes efectos adversos, entre los que se encuentran la osteoporosis y el síndrome metabólico. Ambos están relacionados con la aparición de nefrolitiasis. El objetivo de este estudio es analizar la aparición de nefrolitiasis en pacientes sometidos a este tratamiento con análogos LHRH. Pacientes y métodos: Estudio de casos y controles en el que se incluyeron un total de 85 pacientes divididos en 2 grupos: el grupo 1 estaba formado por 41 pacientes con tratamiento de privación androgénica y el grupo 2 por 44 pacientes sin tratamiento de privación androgénica. Resultados: En el grupo 1 se produjo litiasis de nueva aparición en 12 casos (29,3%) frente a 2 casos en el grupo 2 (4,5%) (p = 0,0001), a los 4,4 años de comenzar el tratamiento de privación androgénica. La odds ratio estimada fue de 8,69 (IC al 95% 1,81-41,76). Conclusión: Parece existir relación entre el tratamiento con análogos LHRH y la litiasis; no obstante, son precisos estudios prospectivos a largo plazo con control metabólico para poder establecer las causas que expliquen la aparición de este fenómeno (AU)
Background and objective: Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue. Patients and methods: Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy. Results: New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P = .0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76). Conclusion: The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy (AU)
Assuntos
Humanos , Masculino , Neoplasias da Próstata/tratamento farmacológico , Antagonistas de Androgênios/efeitos adversos , Pamoato de Triptorrelina/efeitos adversos , Estudos de Casos e Controles , Astenia/induzido quimicamente , Osteoporose/induzido quimicamente , Nefrolitíase/induzido quimicamente , Síndrome Metabólica/induzido quimicamenteAssuntos
Prostatectomia , Robótica , Humanos , Laparoscopia , Masculino , Neoplasias da Próstata/cirurgiaRESUMO
BACKGROUND AND OBJECTIVE: Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue. PATIENTS AND METHODS: Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy. RESULTS: New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P=.0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76). CONCLUSION: The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy.
Assuntos
Antagonistas de Androgênios/efeitos adversos , Antineoplásicos Hormonais/efeitos adversos , Hormônio Liberador de Gonadotropina/efeitos adversos , Cálculos Renais/induzido quimicamente , Neoplasias da Próstata/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Antagonistas de Androgênios/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Seguimentos , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Incidência , Cálculos Renais/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Resultado do TratamentoRESUMO
Different image techniques have been used to analyze mucociliary clearance (MCC) in humans, but current small animal MCC analysis using in vivo imaging has not been well defined. Bitter taste receptor (T2R) agonists increase ciliary beat frequency (CBF) and cause bronchodilation but their effects in vivo are not well understood. This work analyzes in vivo nasal and bronchial MCC in guinea pig animals using three dimension (3D) micro-CT-SPECT images and evaluates the effect of T2R agonists. Intranasal macroaggreggates of albumin-Technetium 99 metastable (MAA-Tc99m) and lung nebulized Tc99m albumin nanocolloids were used to analyze the effect of T2R agonists on nasal and bronchial MCC respectively, using 3D micro-CT-SPECT in guinea pig. MAA-Tc99m showed a nasal mucociliary transport rate of 0.36 mm/min that was increased in presence of T2R agonist to 0.66 mm/min. Tc99m albumin nanocolloids were homogeneously distributed in the lung of guinea pig and cleared with time-dependence through the bronchi and trachea of guinea pig. T2R agonist increased bronchial MCC of Tc99m albumin nanocolloids. T2R agonists increased CBF in human nasal ciliated cells in vitro and induced bronchodilation in human bronchi ex vivo. In summary, T2R agonists increase MCC in vivo as assessed by 3D micro-CT-SPECT analysis.
Assuntos
Albuminas , Pulmão , Depuração Mucociliar/fisiologia , Nanopartículas , Receptores Acoplados a Proteínas G/agonistas , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único/métodos , Microtomografia por Raio-X/métodos , Albuminas/farmacocinética , Albuminas/farmacologia , Animais , Cobaias , Humanos , Pulmão/diagnóstico por imagem , Depuração Mucociliar/efeitos dos fármacosRESUMO
Sildenafil improves the 6-min walking distance in patients with idiopathic pulmonary fibrosis (IPF) and right-sided ventricular systolic dysfunction.We analysed the previously unexplored role of sildenafil on vasoconstriction and remodelling of pulmonary arteries from patients with IPF and pulmonary hypertension (PH) ex vivo Pulmonary arteries from 18 donors without lung disease, nine IPF, eight PH+IPF and four PH patients were isolated to measure vasodilator and anti-contractile effects of sildenafil in isometric organ bath. Ventilation/perfusion was explored in an animal model of bleomycin lung fibrosis.Sildenafil relaxed serotonin (5-HT) pre-contracted pulmonary arteries in healthy donors and IPF patients and, to a lesser extent, in PH+IPF and PH. Sildenafil inhibited 5-HT dose-response contraction curve mainly in PH+IPF and PH, but not in healthy donors. Sildenafil did not impair the ventilation/perfusion mismatching induced by bleomycin. Pulmonary arteries from PH+IPF patients showed a marked expression of phosphodiesterse-5 and extracellular matrix components. Sildenafil inhibited pulmonary artery endothelial and smooth muscle cell to mesenchymal transition by inhibition of extracellular regulated kinases 1 and 2 (ERK1/2) and SMAD3 phosphorylation.These results suggest an absence of direct relaxant effect and a prominent anti-contractile and anti-remodelling role of sildenafil in PH+IPF pulmonary arteries that could explain the beneficial effects of sildenafil in IPF with PH phenotype.
Assuntos
Hipertensão Pulmonar/tratamento farmacológico , Fibrose Pulmonar/tratamento farmacológico , Citrato de Sildenafila/uso terapêutico , Animais , Bleomicina/química , Bleomicina/farmacologia , Modelos Animais de Doenças , Endotélio Vascular/patologia , Matriz Extracelular/metabolismo , Fibroblastos/química , Humanos , Pulmão/patologia , Masculino , Miócitos de Músculo Liso/metabolismo , Miofibroblastos/metabolismo , Artéria Pulmonar/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Ratos , Ratos Wistar , Serotonina/química , Transdução de Sinais , Citrato de Sildenafila/farmacologia , Fator de Crescimento Transformador beta1/metabolismo , Vasoconstrição , VasodilatadoresRESUMO
El objetivo de este trabajo fue determinar y comparar la composición corporal de deportistas chilenos juveniles destacados, pertenecientes a las selecciones nacionales en el año 2011, de diferentes disciplinas deportivas mediante métodos antropométricos. Fueron evaluados 4 grupos de deportistas juveniles de alto rendimiento, con un número total de 92 individuos, pertenecientes a las disciplinas de lucha olímpica, halterofilia, básquetbol y fútbol. La Masa Muscular de los miembros superiores (MMES) es mayor en basquetbolistas y Halterofilistas con 7,49 (±1,25) y 7,50 (±2,54) kg respectivamente, al ser comparado con futbolistas, quienes obtuvieron un promedio de 5,27 (±0,37) kg. Por otra parte la lucha olímpica posee un promedio de masa muscular de 6,46 (±1,50) kg, la cual está por debajo de los basquetbolistas y Halterofilistas, debido a que la utilización de los miembros superiores es menor que en las disciplinas anteriormente mencionadas, pero a su vez, es mayor que la de los futbolistas. No se aprecian diferencias importantes en la masa muscular total, pero que son marcadas en la masa muscular por segmentos. Concluimos que la estimación de la masa muscular total, no es un elemento suficiente para determinar y predecir el rendimiento deportivo de los sujetos, a diferencia de la segmentación de la masa muscular que permite comparar de mejor forma, la manera en que se distribuye este componente en las distintas disciplinas deportivas, mejorando la especificidad del conocimiento.
The aim of this study was to determine and compare by anthropometric methods, the body composition of elite young Chilean athletes, who were part of the 2011 national team in different sports. Four groups of elite young athletes were evaluated, with a total number of 92 individuals belonging to the wrestling, weightlifting, basketball and football disciplines. The muscle mass of the upper extremities (MMES) is higher in basketball players and bodybuilders with 7.49 (±1.25) and 7.50 (±2.54) kg respectively, when compared with players who scored an average of 5.27 (±0.37) kg. Moreover, wrestling has an average muscle mass of 6.46 (±1.50) kg which is below that of basketball players and bodybuilders, because the use of upper limbs is less than in disciplines mentioned above, but in turn, is greater than that of football players. No significant differences in total muscle mass are reported, however, there are marked differences in muscle mass segment. We concluded that the estimate of total muscle mass is not sufficient basis to determine and predict athletic performance of the subjects. Muscle mass segment on the other hand, provides a better comparison range for the way in which this component is distributed among different sports disciplines, improving specific knowledge and information.
Assuntos
Humanos , Adolescente , Adulto Jovem , Composição Corporal , Atletas , Músculos/anatomia & histologia , Chile , AntropometriaRESUMO
The treatment of ureteral lithiasis by extracorporeal shock wave lithotripsy (ESWL) is progressively being abandoned owing to advances in endoscopic lithotripsy. The purpose of this paper is to analyze the causes as to why ESWL is less effective-with a measurable parameter: focal applied energy quotient (FAEQ) that allows us to apply an improvement project in ESWL results for ureteral lithiasis. A prospective observational cohort study with 3-year follow-up and enrollment period was done with three groups of cases. In Group A, 83 cases of ureteral lithiasis were treated by endoscopic lithotripsy using Holmiun:YAG laser. In Group B, 81 cases of ureteral lithiasis were treated by ESWL using Doli-S device (EMSE 220F-XXP). In Group C, 65 cases of ureteral lithiasis were treated by ESWL using Doli-S device (EMSE 220F-XXP) (FAEQ >10). Statistical study and calculation of RR, NNT, Chi-square test, Fisher's exact test, and Student's t test were done. Efficiency quotient (EQ) and focal applied energy quotient [FAEQ = (radioscopy seconds/number of shock waves) × ESWL session J] were analyzed. From the results, the success rate of the treatment using Holmium:YAG laser lithotripsy and ESWL is found to be 94 and 48%, respectively, with a statistically significant difference (p < 0.001). Success rate of endoscopic laser lithotripsy for lumbar ureteral stones was 82% versus 57% of ESWL (p = 0.611). In Group B, FAEQ was 8.12. In Group C, success rate was 93.84% with FAEQ of 10.64%. When we compare results from endoscopic lithotripsy with Holmium:YAG laser in Group B with results from ESWL with FAEQ >10, we do not observe absolute benefit choosing one or the other. In conclusion, the application of ESWL with FAEQ >10, that is, improving radiologic focalization of the calculus and increasing the number of Joules/SW, makes possible a treatment as safe and equally efficient as Holmium:YAG laser lithotripsy in ureteral lithiasis less than 13 mm.